6.21

0.32% -0.02

After Hours: 6.10 -0.11 -1.77%

Emergent Biosolutions Inc (EBS)

Overview News Price History Option Chain Discussions Forecast

Emergent Biosolutions Inc stock is traded at $6.21, with a volume of 998.36K. It is down -0.32% in the last 24 hours and down -17.97% over the past month. Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

Previous Close:

$6.23

Open:

$6.26

24h Volume:

998.36K

Relative Volume:

0.93

Market Cap:

$318.41M

Revenue:

$676.80M

Net Income/Loss:

$-8.60M

P/E Ratio:

-21.95

EPS:

-0.2829

Net Cash Flow:

$135.40M

1W Performance:

+5.08%

1M Performance:

-17.97%

6M Performance:

-29.19%

1Y Performance:

-18.61%

1-Day Range:

$6.14

$6.30

1-Week Range:

$5.80

$6.60

52-Week Range:

$4.36

$14.06

Emergent Biosolutions Inc Stock (EBS) Company Profile

Name

Emergent Biosolutions Inc

Sector

Healthcare (1074)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

240-631-3200

Address

300 PROFESSIONAL DR, GAITHERSBURG, MD

Employee

900

Twitter

@emergentbiosolu

Next Earnings Date

2026-08-05

Latest SEC Filings

EBS's Discussions on Twitter

Compare EBS vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EBS Emergent Biosolutions Inc	6.21	247.14M	676.80M	-8.60M	135.40M	-0.2829
TAK Takeda Pharmaceutical Co Adr	18.45	57.90B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.36	42.89B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.60	43.41B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	75.81	31.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	487.61	22.35B	3.17B	1.29B	1.01B	27.09

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-30-24	Initiated	H.C. Wainwright	Buy
Aug-22-24	Initiated	Rodman & Renshaw	Buy
Mar-07-24	Upgrade	The Benchmark Company	Hold → Buy
Nov-20-23	Resumed	JP Morgan	Underweight
Aug-29-23	Downgrade	The Benchmark Company	Buy → Hold
Apr-10-23	Upgrade	The Benchmark Company	Hold → Buy
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-10-22	Downgrade	The Benchmark Company	Buy → Hold
Apr-29-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-20-22	Upgrade	The Benchmark Company	Hold → Buy
Nov-08-21	Downgrade	The Benchmark Company	Buy → Hold
May-05-21	Downgrade	Argus	Buy → Hold
Apr-07-21	Initiated	The Benchmark Company	Buy
Feb-24-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-19-21	Downgrade	Chardan Capital Markets	Buy → Neutral
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-14-20	Resumed	JP Morgan	Neutral
Jul-31-20	Reiterated	Chardan Capital Markets	Buy
Sep-12-19	Initiated	Guggenheim	Buy
Sep-04-19	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-02-18	Upgrade	Goldman	Neutral → Buy
Aug-03-18	Reiterated	Chardan Capital Markets	Buy
Jun-13-18	Initiated	Argus	Buy
Apr-25-18	Downgrade	Wells Fargo	Outperform → Market Perform
Jan-24-18	Initiated	Goldman	Neutral
Jan-16-18	Reiterated	Chardan Capital Markets	Buy
Jun-28-16	Reiterated	Singular Research	Buy
Apr-15-16	Initiated	Chardan Capital Markets	Buy
Mar-28-16	Initiated	Singular Research	Buy
Feb-19-16	Initiated	Wells Fargo	Outperform
May-15-14	Initiated	Summer Street Research	Buy
May-31-11	Reiterated	WBB Securities	Strong Buy
Jan-10-11	Reiterated	Wedbush	Outperform
Nov-05-10	Reiterated	Wedbush	Outperform
Aug-18-10	Upgrade	WBB Securities	Buy → Strong Buy
Aug-06-10	Reiterated	Caris & Company	Buy

View All

Emergent Biosolutions Inc Stock (EBS) Latest News

Sep 06, 2026

Emergent BioSolutions: Tough 2026 Outlook Warrant Rating Downgrade (NYSE:EBS) - Seeking Alpha

Sep 06, 2026

Sep 04, 2026

Emergent Biosolutions Stock Price Forecast. Should You Buy EBS? - StockInvest.us

Sep 04, 2026

Sep 03, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioS - The National Law Review

Sep 03, 2026

Emergent BioSolutions repurchases $75 million in senior notes By Investing.com - Investing.com Australia

Sep 03, 2026

Emergent BioSolutions Repurchases $75 Million of Debt at Discount - citybiz

Sep 03, 2026

Emergent BioSolutions faces securities fraud pr... - Pluang

Sep 03, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc.EBS - PR Newswire

Sep 03, 2026

Gaithersburg's Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS - BioBuzz

Sep 03, 2026

Emergent BioSolutions repurchases $75 million in senior notes - Investing.com

Sep 03, 2026

Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes, Reducing Debt to $364.7 Million - Quiver Quantitative

Sep 03, 2026

Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes - marketscreener.com

Sep 03, 2026

Sep 01, 2026

Emergent BioSolutions | 8-K: Current report - Moomoo

Sep 01, 2026

Emergent BioSolutions receives $24 million BARDA contract - grafa.com

Sep 01, 2026

2026-09-01 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Shareholders to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse

Sep 01, 2026

Emergent BioSolutions Inc. Receives Contract Modification Valued At Approximately USD 24 Million From The Biomedical Advanced Research And Development Authority To Supply CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) - marketscreener.com

Sep 01, 2026

EBS Looks 11.9% Overvalued on GF Value™ Amid Challenging Growth Outlook - GuruFocus

Sep 01, 2026

Emergent BioSolutions receives $24M anthrax vaccine contract - Investing.com

Sep 01, 2026

Emergent BioSolutions receives $24M anthrax vaccine contract By Investing.com - Investing.com Nigeria

Sep 01, 2026

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) - The Manila Times

Sep 01, 2026

Emergent BioSolutions Awarded $24M CYFENDUS Contract | EBS Stock News - Stock Titan

Sep 01, 2026

Aug 31, 2026

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray - Bioscience Association Manitoba

Aug 31, 2026

EBS Looks 8.4% Overvalued on GF Value™ Amid Challenging Growth O - GuruFocus

Aug 31, 2026

Emergent BioSolutions wins Canada contract for overdose spray By Investing.com - Investing.com Nigeria

Aug 31, 2026

Emergent BioSolutions wins Canada contract for overdose spray - Investing.com Canada

Aug 31, 2026

Emergent BioSolutions Expands Ready to Rescue Campaign on U.S. Campuses and in Canada for International Overdose Awareness Day - Quiver Quantitative

Aug 31, 2026

Canadian public agencies can buy NARCAN for three years; the spray lasts four - Stock Titan

Aug 31, 2026

Aug 30, 2026

2026-08-30 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Investors to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse

Aug 30, 2026

Aug 28, 2026